Yum! Brands: Fear Is On The Menu

Yum! Brands faces a cyclosporiasis outbreak, but the impact appears less severe than past industry incidents, with no fatalities and effective recalls underway. I revise my price target on YUM to ~$165.60 per share, reflecting a modest 12.6% upside from current levels and factoring in a minor EBITDA headwind. I reissue a 'Buy' rating, citing satisfactory total return potential when including YUM's 2% dividend yield and prospective share buybacks. Key risks include outbreak duration, potential EBITDA impact of $2.6–$2.7B, and possible market multiple compression to ~18x EBITDA.

It's not every day that 'explosive diarrhea' becomes an investment topic, but here we are. Yum! Brands ( YUM ) was back in everyone's mouth this week because of the cyclosporiasis outbreak that started in May.